• Passa al contenuto principale
BC

biochimica clinica

it_IT Italian
it_IT Italian en_US English
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

RASSEGNE - Reviews

Volume:

Biochimica Clinica 2020; 44(4) 335-350

Pubblicato on-line:

Ottobre 16, 2020

DOI:

10.19186/BC_2020.086

Scarica in PDF:

Farmacotossicologia e metodologie di analisi dell’acido gamma-idrossibutirrico nel laboratorio clinico e forense
Pharmacotoxicology and analytical issues of gamma-hydroxybutyric acid in clinical and forensic laboratory

AUTORI

Emilia Marchei1, Maria Concetta Rotolo1, Silvia Graziano1, Manuela Pellegrini1, Alessandro del Rio2
1Centro Nazionale Dipendenze e Doping, Istituto Superiore di Sanità, Roma
2Dipartimento di Scienze Anatomiche, Istologiche, Forensi e Ortopediche, Sapienza Università, Roma

ABSTRACT

Pharmacotoxicology and analytical issues of gamma-hydroxybutyric acid in clinical and forensic laboratory

Gamma-hydroxybutyric acid (GHB) can be considered both an endogenous metabolite and a precursor of the neurotransmitter gamma-aminobutyric acid (GABA) acting within the central nervous system as a neuromodulator.
Pharmacologically, GHB is classified as a central nervous system depressant and its mechanism of action involves interaction and binding with GABA-B receptors.
With the generic name of sodium oxybate, the sodium salt of GHB, is sold as a pharmaceutical product under the trade name of Xyrem® when prescribed for the treatment of people with narcolepsy and with the name of Alcover® when used to relieve alcohol withdrawal syndrome and treat alcohol dependence.
Between the end of the 90s of the twentieth century and the beginning of the twenty-first one, the abuse of GHB became increasingly widespread in the recreational field. The substance, often consumed in combination with alcohol, cannabis, ecstasy (3,4-Methylenedioxymethamphetamine, MDMA), ketamine, has been converted in one of the most used “club drugs”, becoming one of the most serious health issues in the emergency department of many European and extra-European Countries because of the initial difficult clinical management of the growing number of cases of intoxication. At the same time, there was an increase of cases of sexual assaults of victims who were unaware they had been given GHB as odourless and colourless sedative substance.
In this narrative review, the three different aspects of GHB as endogenous neuromodulator, as prescription drug and as substance of abuse are illustrated. The main methods for qualitative and quantitative analysis in conventional and non-conventional biological matrices for clinical and forensic purposes are also described.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967